vivoslife.com - יחס שווי חברה להכנסות VVOS

Vivos Therapeutics (VVOS) possesses significant pricing power driven by its unique mask-free apnea treatment method. The company's price-to-sales ratio reflects the dynamics of this advantage, where the 538.72 level represents the current value. Market capitalization is supported by the sale of proprietary oral systems. Leveraging regulatory approvals, the business is effectively displacing bulky alternatives and steadily expanding its presence within the medical equipment niche.
VVOS (Vivos Therapeutics, Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The EV/Sales multiple determines the total value of a business, including net debt, relative to annual sales volume, allowing for an assessment of an asset's market value regardless of its financing structure. The EV/Sales multiple trend for Vivos Therapeutics (VVOS) reflects the capitalization potential of its unique non-invasive sleep apnea treatment technology, confirming the company's fundamental resilience driven by high confidence from the professional medical community.